Tech Company Financing Transactions
Aligos Therapeutics Funding Round
Wellington Management Company, Boxer Capital and Cormorant Asset Management participated in a $125 million Series B venture round for Aligos Therapeutics. The financing round was announced on 1/13/2020.
Transaction Overview
Company Name
Announced On
1/13/2020
Transaction Type
Venture Equity
Amount
$125,000,000
Round
Series B
Investors
Proceeds Purpose
This round of funding provides Aligos with the capital needed to move our portfolio of products aimed at treatment of chronic hepatitis B into clinical development.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Corporate Drive 2nd Floor
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Aligos Therapeutics (Nasdaq: ALGS) discovers targeted antiviral therapies for chronic hepatitis B (CHB), COVID-19, and optimized therapeutics for Nonalcoholic Steatohepatitis (NASH).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lawrence Blatt
Chief Financial Officer
Lesley Calhoun
Chief Medical Officer
Matthew McClure
Chief Scientific Officer
Julian Symons
President
Leonid Beigelman
VP - General Counsel
Lucinda Quan
Browse more venture capital transactions:
Prev: 1/13/2020: IsoPlexis venture capital transaction
Next: 1/13/2020: Tyton BioSciences venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs